February 14, 2020
Chugai Pharmaceutical’s anti-CD79b antibody-drug conjugate (ADC) polatuzumab vedotin met the primary endpoint in a Japan PII study for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the company said on February 13. According to topline data from...read more